Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG(4) response

BACKGROUND: BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins consisting of hepatitis B-derived PreS and hypoallergenic peptides from the major timothy grass pollen allergens adsorbed on aluminium hydroxide has been shown to be safe and to improve clinical symptoms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckl-Dorna, Julia, Weber, Milena, Stanek, Victoria, Linhart, Birgit, Ristl, Robin, Waltl, Eva E., Villazala-Merino, Sergio, Hummel, Andrea, Focke-Tejkl, Margarete, Froeschel, Renate, Neubauer, Angela, Henning, Rainer, Perkmann, Thomas, Valenta, Rudolf, Niederberger, Verena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921329/
https://www.ncbi.nlm.nih.gov/pubmed/31786130
http://dx.doi.org/10.1016/j.ebiom.2019.11.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921329/
https://www.ncbi.nlm.nih.gov/pubmed/31786130
http://dx.doi.org/10.1016/j.ebiom.2019.11.006

Ejemplares similares